210530-71-5

Basic information

• Product Name: 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER
• Synonyms: 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER;3,4-difluoro acetate;Methyl 2-(3,4-difluorophenyl)acetate
• CAS NO: 210530-71-5
• Molecular Formula: C₉H₈F₂O₂
• Molecular Weight: 186.16
• Mol File: 210530-71-5.mol

Chemical Properties

• Boiling Point: 211°C at 760 mmHg
• Flash Point: 79.4°C
• Appearance: /
• Density: 1.235g/cm³
• Vapor Pressure: 0.187mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER(210530-71-5)
• EPA Substance Registry System: 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER(210530-71-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 210530-71-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research and Development:
3,4-Difluorophenylacetic Acid Methyl Ester is used as a research compound for exploring its chemical properties and potential applications in various fields. Its unique molecular structure with fluorine atoms and an ester group may offer interesting reactivity and interaction patterns that could be valuable in the synthesis of new compounds or materials.
Used in Pharmaceutical Industry:
3,4-Difluorophenylacetic Acid Methyl Ester is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. The presence of fluorine atoms can significantly influence the biological activity and properties of the resulting molecules, making 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER a potentially useful building block in the development of new drugs.
Used in Material Science:
3,4-Difluorophenylacetic Acid Methyl Ester is used as a component in the development of new materials with specific properties. The incorporation of 3,4-DIFLUOROPHENYLACETIC ACID METHYL ESTER into polymers or other materials could lead to the creation of materials with enhanced characteristics, such as improved thermal stability, chemical resistance, or other desirable properties.

InChI:InChI=1/C9H8F2O2/c1-13-9(12)5-6-2-3-7(10)8(11)4-6/h2-4H,5H2,1H3

Upstream product

• 67-56-1 methanol 
• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 949167-80-0 1-amino-3-(3,4-difluorophenyl)piperidin-2-one 
• 1227845-76-2 N'-[2-(3,4-difluorophenyl)acetyl]-2-ethyl-4-methoxy-3-methyl-benzohydrazide 
• 1227845-44-4 N'-[2-(3,4-Difluorophenyl)acetyl]-2-ethyl-4-hydroxy-3-methylbenzohydrazide 
• 797784-35-1 2-(3,4-difluorophenyl)-acetic hydrazide 
• 300356-37-0 3-cyclopentyl-2-(3,4-difluorophenyl)propionic acid methyl ester 
• 557798-56-8 methyl 2-bromo-2-(3,4-difluorophenyl)acetate 
• 306761-16-0 methyl 2-methyl-2-(3,4-difluorophenyl)propionate 
• 741682-83-7 C₁₁H₁₀F₂O₂ 
• 476472-54-5 2-(3,4-difluoro-phenyl)-1-(6-methyl-pyridin-2-yl)-ethanone 
• 619323-37-4 2-(3,4-difluorophenyl)pent-4-enoic acid 
• 619323-50-1 3-(3,4-difluorophenyl)-5-methyltetrahydrofuran-2-one 
• 619323-21-6 methyl 2-(3,4-difluorophenyl)pent-4-enoate 

Relevant articles and documents

Blue Light-Promoted N?H Insertion of Carbazoles, Pyrazoles and 1,2,3-Triazoles into Aryldiazoacetates

Blue light irradiation of aryldiazoacetates leads to the formation of free carbenes, which can react with carbazoles, pyrazoles and 1,2,3-triazoles to afford the corresponding N?H inserted products. These reactions are performed under air and at room temperature, allowing the mild preparation of a variety of motifs found in biologically relevant targets. (Figure presented.).

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2 R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N- thiazol-2-yl-propionamide (RO0281675)

Glucokinase (GK) is a glucose sensor that couples glucose metabolism to insulin release. The important role of GK in maintaining glucose homeostasis is illustrated in patients with GK mutations. In this publication, identification of the hit molecule 1 and its SAR development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described. Compound 21a (RO0281675) was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.

Synthesis and structure-antifungal activity relationships of 3-aryl-5-alkyl-2,5-dihydrofuran-2-ones and their carbanalogues: Further refinement of tentative pharmacophore group

Two series of 3-(substituted phenyl)-5-alkyl-2,5-dihydrofuran-2-ones related to a natural product, (-)incrustoporine, were synthesized and their in vitro antifungal activity evaluated. The compounds with halogen substituents on the phenyl ring exhibited selective antifungal activity against the filamentous strains of Absidia corymbifera and Aspergillus fumigatus. On the other hand, the influence of the lenghth of the alkyl chain at C(5) was marginal. The antifungal effect of the most active compound against the above strains was higher than that of ketoconazole, and close to that of amphotericin B. In order to verify the hypothesis about a possible relationship between the Michael-accepting ability of the compounds and their antifungal activity, a series of simple carbanalogues, 2-(substituted phenyl)cyclopent-2-enones, was prepared and subjected to antifungal activity assay as well.

Heterosubstituted pyridine derivatives as PDE4 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). or a pharmaceutically acceptable salt or hydrate thereof. The invention also encompasses pharmaceutical compositions and methods for treatment.

Heteroaromatic glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.